(Q33397543)

26 July 2017

title

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma (English)

1 reference

26 July 2017

1 reference

2

E Q Lee

1 reference

26 July 2017

1

J Drappatz

1 reference

26 July 2017

4

S A Grimm

1 reference

26 July 2017

5

A D Norden

1 reference

26 July 2017

10

T T Batchelor

1 reference

26 July 2017

13

D C Lafrankie

1 reference

26 July 2017

16

J J Raizer

1 reference

26 July 2017

S. Hammond

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

R. Beroukhim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

M. Gerard

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

D. Schiff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

A. S. Chi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

L. M. Doherty

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

A. S. Ciampa

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

D. C. Lafrankie

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

S. Ruland

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

S. M. Snodgrass

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

P. Y. Wen

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21984064

14 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21984064

14 December 2024

publication date

8 October 2011

1 reference

full work available at URL

26 July 2017

http://link.springer.com/content/pdf/10.1007/s11060-011-0717-z.pdf

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0717-Z

http://link.springer.com/article/10.1007/s11060-011-0717-z/fulltext.html

14 December 2024

file format

HyperText Markup Language

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0717-Z

http://link.springer.com/content/pdf/10.1007/s11060-011-0717-z

14 December 2024

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0717-Z

Journal of Neuro-Oncology

14 December 2024

published in

1 reference

26 July 2017

volume

107

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

133-138

1 reference

Malignant gliomas in adults

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0717-Z

Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21984064

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Characteristics of Thrombocytopenia in Patients Treated with Oral Panobinostat (LBH589).

27

1 reference

https://api.crossref.org/works/10.1007/S11060-011-0717-Z

14 December 2024

Identifiers

1 reference

Dimensions Publication ID

26 July 2017

1031708957

0 references

1 reference